Elevated CXCL13 levels in the CSF have been demonstrated for CNS lymphomas (72), and when elevated together with IL-10 in the CSF, CXCL13 has a >99% specificity for primary and secondary lymphomas, leading to similar proposals that it serves as a biomarker for non-Hodgkin lymphoma involving the CNS (73). This evidence concerns the gene CXCL13 and non-Hodgkin lymphoma.